培美曲塞联合顺铂治疗非小细胞肺癌的临床效果及安全性分析  

Clinical efficacy and safety of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer

作　　者：张志蓉 买吐地·吾布来山 ZHANG Zhi-rong;MAITUDI·Wubulaishan(People's Hospital of Hotan Prefecture,Hotan 848000,China)

机构地区：[1]和田地区人民医院,848000

出　　处：《中国实用医药》2023年第14期99-102,共4页China Practical Medicine

摘　　要：目的分析非小细胞肺癌患者接受培美曲塞联合顺铂治疗的临床效果与安全性。方法52例接受放化疗治疗的非小细胞肺癌患者为研究对象,随机分为参照组与研究组,各26例。参照组应用顺铂治疗,研究组应用顺铂联合培美曲塞治疗。对比两组临床疗效、毒副反应发生情况及治疗前后血清肿瘤标志物水平。结果研究组近期治疗总有效率84.62%和总控制率96.15%均高于参照组的53.85%、73.08%,差异有统计学意义(P<0.05)。治疗后,研究组癌胚抗原(CEA)(12.39±4.12)ng/ml、糖类抗原125(CA125)(46.56±5.26)U/ml、细胞角蛋白19(CK-19)(2.29±0.88)ng/ml均低于参照组的(16.96±4.36)ng/ml、(63.87±5.54)U/ml、(3.98±0.29)ng/ml,差异有统计学意义(P<0.05)。研究组肝功能异常、血小板减少、胃肠不适、贫血、白细胞减少、恶心呕吐发生率均低于参照组,差异均有统计学意义(P<0.05)。结论将培美曲塞联合顺铂应用于非小细胞肺癌的治疗中,对于降低肿瘤标志物水平,提高近期疗效,控制疾病进展有积极意义,而且毒副反应发生较少,安全性相对较高。Objective To analyze the clinical effect and safety of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer.Methods A total of 52 patients with non-small cell lung cancer receiving chemoradiotherapy were studied and randomly divided into the reference group and the research group,with 26 cases in each group.The reference group was treated with cisplatin,and the research group was treated with cisplatin and pemetrexed.The clinical efficacy,adverse reactions and serum tumor marker levels before and after treatment were compared between the two groups.Results The total effective rate of recent treatment of the research group was 84.62%and the total control rate was 96.15%,which were higher than those of the reference group(53.85%and 73.08%),and the differences were statistically significant(P<0.05).After treatment,the research group had carcinoembryonic antigen(CEA)of(12.39±4.12)ng/ml,carbohydrate antigen 125(CA125)of(46.56±5.26)U/ml and cytokeratin 19(CK-19)of(2.29±0.88)ng/ml,which were lower than those of(16.96±4.36)ng/ml,(63.87±5.54)U/ml and(3.98±0.29)ng/ml in the reference group,and the differences were statistically significant(P<0.05).The incidence of abnormal liver function,thrombocytopenia,gastrointestinal discomfort,anemia,leukopenia,nausea and vomiting were lower than those in the reference group,and the differences were statistically significant(P<0.05).Conclusion The application of pemetrexed combined with cisplatin in the treatment of non-small cell lung cancer is of positive significance for reducing the level of tumor markers,improving the short-term curative effect and controlling the progress of the disease,with less toxic and side effects and relatively high safety.

关 键 词：培美曲塞 顺铂 非小细胞肺癌 治疗效果 安全性 

分 类 号：R734.2[医药卫生—肿瘤]